- |||||||||| levetiracetam / Generic mfg., levetiracetam low dose (AGB101) / AgeneBio
NEURONAL PENTRAXIN 2: BIOMARKER AND MECHANISM ACROSS THE AGING/ALZHEIMER’S SPECTRUM. () - Oct 20, 2019 - Abstract #CTAD2019CTAD_297;
P3
Notably, an increase in NPTX2 produced by low dose levetiracetam administration may contribute to the reduction of neural overactivity and cognitive improvement previously reported with this aged rat model of memory impairment (Koh et al. 2010; Haberman et al.
- |||||||||| humanised dinutuximab (Hu14.18K322A) / Essential Pharma
Enrollment closed, Metastases: Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov) - Oct 16, 2019
P2, N=153, Active, not recruiting,
It is important that obstetricians timely recognize the condition. Recruiting --> Active, not recruiting
- |||||||||| levetiracetam / generics
Clinical, Review, Journal: New-onset epilepsy in the elderly. (Pubmed Central) - Oct 13, 2019
There is a need for more RCTs that investigate effective treatments with limited side effects. More research studies on the psychosocial effects of new onset epilepsy, and long-term outcomes, for people aged 60 years are also required.
- |||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. (Pubmed Central) - Oct 9, 2019
Levetiracetam is significantly more effective than phenytoin for the treatment of convulsive status epilepticus in children who have failed to respond to benzodiazepines. Simulation with the adult brivaracetam PK/PD model in combination with an existing pediatric brivaracetam population PK model allowed characterization of the dose-response curve, suggesting maximum response at brivaracetam 4 mg/kg/day dosing (capped at 200 mg/day, the maximum adult dose) in children aged ≥4 years.
- |||||||||| levetiracetam / Generic mfg., topiramate / Generic mfg.
Enrollment closed, Enrollment change, Monotherapy: A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy (clinicaltrials.gov) - Oct 7, 2019
P3, N=63, Active, not recruiting,
This work should be replicated on a larger scale to determine if significant changes are occurring in the MCM rate, which would allow a robust economic estimate of the benefits of improvements in prescribing practice and the personal effect of such changes. Recruiting --> Active, not recruiting | N=282 --> 63
- |||||||||| vigabatrin / Generic Mfg.
Retrospective data, Journal, Combination therapy: Optimized Treatment for Infantile Spasms: Vigabatrin versus Prednisolone versus Combination Therapy. (Pubmed Central) - Oct 5, 2019
For patients who used prednisolone, the proportion of responders was significantly higher in the higher-dose group (≥40 mg/day) than in the lower-dose group (66.7% vs. 12.5%, p = 0.028). Further studies of combination therapy to assess dosage protocols and long-term outcomes are needed.
- |||||||||| Briviact (brivaracetam) / UCB
Clinical, Journal: Brivaracetam in the treatment of epilepsy: a review of clinical trial data. (Pubmed Central) - Oct 3, 2019
In this setting, immediate switch from LEV to BRV at a 10:1-15:1 ratio without titration is feasible. Further research is needed to examine the long-term tolerability and efficacy of BRV as well as its role in the treatment of other types of epilepsies, particularly dementia-related epilepsy and brain tumor-related epilepsy.
- |||||||||| carbamazepine / Generic Mfg.
Retrospective data, Journal, Monotherapy: The Risk Of Seizure-Related Hospitalization Among Older Adults On Levetiracetam Monotherapy: A Retrospective Comparative Cohort Study. (Pubmed Central) - Oct 3, 2019
Patients on levetiracetam were more than twice as likely to be hospitalized due to seizures within the 24 months of follow-up compared to their counterparts on other AEDs (RR=2.76, 95% CI=1.16-6.53, P=0.021). This study suggests that older adults on old generation AEDs such as phenytoin, carbamazepine, and valproic acid appear to have a lower risk of seizure-related hospitalization compared to their counterparts on levetiracetam.
- |||||||||| levetiracetam / Generic mfg.
Clinical, PK/PD data, Journal: Levetiracetam Pharmacokinetics in a Critically Ill Anephric Patient on Intermittent Hemodialysis. (Pubmed Central) - Oct 2, 2019
Insufficient intradialytic or post-dialysis levetiracetam concentrations may place patients at risk of breakthrough seizures. This case indicates that dialysis patients on levetiracetam may require higher post-dialysis supplemental doses than currently recommended and tailored therapy supported by therapeutic drug monitoring.
- |||||||||| lacosamide / Generic Mfg.
Biomarker, Journal: Electronic Health Data Predict Outcomes After Aneurysmal Subarachnoid Hemorrhage. (Pubmed Central) - Oct 2, 2019
Variance in early physiologic data can impact patient outcomes and may serve as targets for early goal-directed therapy. Electronically retrievable features such as ICP, glucose levels, and electroencephalography patterns should be considered in disease severity and risk stratification scores.
- |||||||||| carbamazepine / Generic Mfg., Trileptal (oxcarbazepine) / Novartis
Journal, Adverse events: Adverse Pregnancy Outcomes Associated With Gestational Exposure to Antiepileptic Drugs. (Pubmed Central) - Oct 2, 2019
These caveats notwithstanding, guidance should err on the side of caution. Therefore, a conservative conclusion is that whereas analyses based on exposures in 2,000-4,000 pregnancies suggest that lamotrigine and carbamazepine are not associated with an increased risk of fetal loss, IUGR, and preterm birth, there is insufficient evidence to either firmly indict or firmly exonerate the other AEDs with regard to these outcomes.
- |||||||||| levetiracetam / generics
Journal: Effects of levetiracetam on astroglial release of kynurenine-pathway metabolites. (Pubmed Central) - Oct 2, 2019
This study demonstrated several mechanisms of LEV: 1) inhibition of AMPA- and AdA-induced astroglial release, 2) inhibition of IFNγ-induced IP3-receptor activation, and 3) inhibition of release of cinnabarinic acid and quinolinic-acid with activation of that of kynurenic-acid induced by IFNγ. These combinations of actions of LEV may contribute to the unique profiles of LEV.
- |||||||||| carbamazepine / Generic Mfg., Trileptal (oxcarbazepine) / Novartis
Journal: Major Congenital Malformations Associated With Exposure to Antiepileptic Drugs During Pregnancy. (Pubmed Central) - Oct 2, 2019
In the AEDs associated with elevated risks, the extent to which the risks are due to confounding by indication is unknown. Importantly, confounding by indication notwithstanding, at conventional doses lamotrigine, levetiracetam, and oxcarbazepine, and possibly zonisamide and gabapentin, as well, are associated with absolute MCM risks that are no greater than the 2%-3% MCM risk in the general population.
- |||||||||| levetiracetam / generics
Journal: Levetiracetam-mediated improvement of decreased NMDA-induced glutamate release from nerve terminals during hypothermia. (Pubmed Central) - Oct 2, 2019
Therefore, levetiracetam administration significantly mitigated a hypothermia-induced decrease in NMDA receptor response at the presynaptic level and can be used for the targeted neurocorrection to reduce side effects of hypothermia in cardiac surgery. However, levetiracetam-mediated improvement of NMDA receptor response is not applicable in stroke, brain trauma and neonatal asphyxia therapies, where the main neuroprotective action of hypothermia is associated with prevention of damaging consequence of pre-existing acute glutamate exitotoxicity.
- |||||||||| levetiracetam / Generic mfg.
Trial completion date, Trial primary completion date: Levetiracetam in Early Psychosis (clinicaltrials.gov) - Oct 1, 2019
P2, N=32, Recruiting,
However, levetiracetam-mediated improvement of NMDA receptor response is not applicable in stroke, brain trauma and neonatal asphyxia therapies, where the main neuroprotective action of hypothermia is associated with prevention of damaging consequence of pre-existing acute glutamate exitotoxicity. Trial completion date: Jun 2019 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Oct 2019
- |||||||||| Review, Journal: Pregabalin add-on for drug-resistant focal epilepsy. (Pubmed Central) - Sep 30, 2019
Results demonstrated efficacy for doses from 150 mg/day to 600 mg/day, with increasing effectiveness at 600 mg doses, however issues with tolerability were noted at higher doses. The trials included in this review were of short duration, and longer-term trials are needed to inform clinical decision making.
- |||||||||| carbamazepine / Generic Mfg., Aptiom (eslicarbazepine) / Sumitomo Dainippon, Eisai
Clinical, Journal: Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures. (Pubmed Central) - Sep 28, 2019
Model-based simulations were subsequently performed to apply target exposure matching of selected ESL doses for pediatric subjects (aged 4-17 years) to attain eslicarbazepine exposures associated with effective and well-tolerated ESL doses in adults. Overall, model-based exposure matching allowed for extrapolation of efficacy to support pediatric dose selection as part of the submission to obtain FDA approval for ESL (adjunctive therapy and monotherapy) in subjects aged 4-17 years, without requiring an additional clinical study.
- |||||||||| Trileptal (oxcarbazepine) / Novartis
Clinical, PK/PD data, Review, Journal: Pharmacokinetic Considerations with the Use of Antiepileptic Drugs in Patients with HIV and Organ Transplants. (Pubmed Central) - Sep 28, 2019
Antiepileptic drugs with no or minimal enzyme-inducing properties include brivaracetam, gabapentin, lacosamide, lamotrigine, levetiracetam, perampanel, pregabalin, and vigabatrin. The newer generations of antiepileptic drugs have expanded the therapeutic options in patients with HIV infection or organ transplants.
- |||||||||| Fycompa (perampanel) / Eisai
Journal: Effect of newer anti-epileptic drugs (AEDs) on the cognitive status in pentylenetetrazol induced seizures in a zebrafish model. (Pubmed Central) - Sep 28, 2019
The gene expression levels of Brain-Derived Neurotrophic Factor (BDNF), Neuropeptide Y (NPY) and Cyclic Adenosine Monophosphate (CAMP) Responsive Element Binding Protein 1 (CREB-1) were not found to be significantly different in AED treated zebrafish. Based on the experimental results, a decrease in brain glutamate levels due to AED treatment appears to be at least one of the major factors behind the observed cognitive impairment in the treated zebrafish.
- |||||||||| levetiracetam / generics
Journal: Multiple hemorragic brain lesions revealing metastatic melanoma (Pubmed Central) - Sep 27, 2019
Epileptic seizures were controlled with levetiracetam. In patient with multiple hemorrhagic and spontaneous brain lesions, it is essential to obtain informations on patient's history of melanoma and to perform a thorough dermatologic examination in order to investigate its cause and to establish adequate therapeutic treatment.
- |||||||||| levetiracetam / generics
ANAPHYLAXIS FOLLOWING IV LEVETIRACETAM: DIAGNOSED BY TRYPTASE IN THE ICU (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3455;
This case demonstrates the importance of considering anaphylaxis as a cause of shock. Additionally, in patients already in the ICU where signs and symptoms of anaphylaxis may be difficult to elucidate, obtaining a tryptase level may be helpful.
- |||||||||| ceftriaxone / Generic Mfg.
UNCOMMON FOE: GROUP B STREPTOCOCCUS MENINGITIS, NO LONGER JUST FOR NEONATES (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 5) - Sep 25, 2019 - Abstract #CHEST2019CHEST_3342;
This case highlights that timely recognition of the antimuscarinic toxidrome and that appropriate use of physostigmine is crucial in patients with severe anticholinergic toxicity. With noted elevated intracranial pressure (ICP), lumbar drain was placed for ICP monitoring and started on acetazolamide...Antibiotics were switched to ceftriaxone covering sinusitis pathogens, and he was successfully extubated on day 12 with complete neurological recovery.Bacterial meningitis can have devastating effects...The key to decreasing the morbidity and mortality associated with GBS is early recognition, appropriate antibiotics and source control.
- |||||||||| clonazepam / generics, levetiracetam / generics, ioflupane / generics
Novel Mutation of NUS1 Gene Presenting With Developmental And Epileptic Encephalopathy and Movement Disorders (Les Muses Terrace, Level 3) - Sep 24, 2019 - Abstract #MDSCongress2019MDS_734;
Our patient presents with ataxia, intentional tremors and prominent action myoclonus of arms and facial myoclonus, likely due to cortical and cerebellar involvement. We also demonstrate evidence of nigrostriatal degeneration, an interesting finding in light of a recent report of NUS1 as possible candidate gene for early onset Parkinson’s disease. NUS1 encodes for Nogo-B receptor (NgBR) which along with dehydrodolichyl diphosphate synthase (DHDDS) are critical for protein glycosylation.
- |||||||||| NN1213 / Novo Nordisk
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: SPAR: Seizure Prophylaxis in Aneurysm Repair (clinicaltrials.gov) - Sep 19, 2019
P4, N=79, Active, not recruiting,
In our study, we found pyridoxine to be safe and effective in controlling LEV-induced BAEs in children. Recruiting --> Active, not recruiting | N=400 --> 79 | Trial completion date: Feb 2020 --> Jun 2020 | Trial primary completion date: Feb 2020 --> Jun 2020
- |||||||||| Briviact (brivaracetam) / UCB
Clinical, Review, Journal: Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. (Pubmed Central) - Sep 17, 2019
BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.
|
